STEMCELL Technologies  announced on 4/25/18 a $45 million joint funding agreement between the Governments of Canada and British Columbia to help the company build a state-of-the-art advanced manufacturing facility. The funding agreement will accelerate the Vancouver company’s rapidly scaling business of providing cutting-edge reagents and tools to support life science researchers around the world working in the cell therapy and regenerative medicine fields.

STEMCELL provides cell culture media, cell isolation products, accessory tools and educational services for life science research. STEMCELL provides over 2500 products to more than 90 countries worldwide.

The five-year, $138 million project will build a new advanced manufacturing facility for biologics in Burnaby, British Columbia. This new facility will make it possible for STEMCELL to manufacture its products at the higher regulatory compliance standard required to support clinical trials in the rapidly evolving sciences of cell therapy, tissue engineering, immunotherapy, gene therapy and regenerative medicine, with the ultimate aim of curing cancer and other serious diseases.

The Federal contribution will come from the Strategic Innovation Fund Program managed by the Ministry of Innovation, Science and Economic Development.